UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?

Guedan, Sonia; Luu, Maik; Ammar, Delphine; Barbao, Paula; Bonini, Chiara; Bousso, Philippe; Buchholz, Christian J; ... Marchiq, Ibtissam; + view all (2022) Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside? Journal for ImmunoTherapy of Cancer , 10 (5) , Article e003487. 10.1136/jitc-2021-003487. Green open access

[thumbnail of e003487.full.pdf]
Preview
Text
e003487.full.pdf - Published Version

Download (1MB) | Preview

Abstract

Immunotherapy with gene engineered CAR and TCR transgenic T-cells is a transformative treatment in cancer medicine. There is a rich pipeline with target antigens and sophisticated technologies that will enable establishing this novel treatment not only in rare hematological malignancies, but also in common solid tumors. The T2EVOLVE consortium is a public private partnership directed at accelerating the preclinical development of and increasing access to engineered T-cell immunotherapies for cancer patients. A key ambition in T2EVOLVE is to assess the currently available preclinical models for evaluating safety and efficacy of engineered T cell therapy and developing new models and test parameters with higher predictive value for clinical safety and efficacy in order to improve and accelerate the selection of lead T-cell products for clinical translation. Here, we review existing and emerging preclinical models that permit assessing CAR and TCR signaling and antigen binding, the access and function of engineered T-cells to primary and metastatic tumor ligands, as well as the impact of endogenous factors such as the host immune system and microbiome. Collectively, this review article presents a perspective on an accelerated translational development path that is based on innovative standardized preclinical test systems for CAR and TCR transgenic T-cell products.

Type: Article
Title: Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1136/jitc-2021-003487
Publisher version: http://dx.doi.org/10.1136/jitc-2021-003487
Language: English
Additional information: © Author(s) (or their employer[s]) 2022. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license (http://creativecommons.org/licenses/by-nc/4.0/).
UCL classification: UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL
URI: https://discovery.ucl.ac.uk/id/eprint/10149205
Downloads since deposit
12Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item